14/01/2025  10:20:16 Chg. +1.2000 Volume Bid07:39:59 Ask07:39:59 Market Capitalization Dividend Y. P/E Ratio
5.8000EUR +26.09% 4,060
Turnover: 23,122
5.0600Bid Size: 100 5.6400Ask Size: 90 58.66 mill.EUR - -

Business description

The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.
 

Management board & Supervisory board

CEO
Dr. Jason Loveridge
Management board
Dr. med. Susanne Danhauser-Riedl, Kathleen Masch-Wiest
Supervisory board
Dr. Clemens Doppler, Dr. Irina Antonijevic, Dr. Manfred Rüdiger, Helmut Jeggle, Prof. Dr. Helga Rübsamen-Schaeff
 

Company data

Name: 4SC AG
Address: Fraunhoferstraße 22,D-82152 Planegg-Martinsried
Phone: +49-89-700763-0
Fax: -
E-mail: -
Internet: www.4sc.de
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 31/12
Free Float: -
IPO date: 15/12/2005

Investor relations

Name: -
IR phone: -
IR Fax: -
IR e-mail: ir-pr@4sc.com

Company calendar

CW 13 | 28/03/2025 4th Quarter/Annual Report
CW 16 | 17/04/2025 Interim Report 1st Quarter/3 Months
CW 29 | 16/07/2025 General Shareholder Meeting
CW 32 | 08/08/2025 Interim Report 2nd Quarter/6 Months
CW 42 | 17/10/2025 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Santo Holding
 
52.10%
Others
 
27.50%
ATS Beteiligungsverwaltung
 
20.40%